Livzon Pharma to Acquire Roughly 0.13% Stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan

Stock News
11/11

Livzon Pharma (01513) has announced that on November 11, 2026, the company entered into a share transfer agreement with Zhonghuiyuan regarding Xinbeijiang Pharmaceutical, agreeing to acquire approximately 0.13% of Xinbeijiang Pharmaceutical's shares held by Zhonghuiyuan for a cash consideration of approximately RMB 3.8525 million, corresponding to approximately RMB 303,600 of Xinbeijiang Pharmaceutical's registered capital.

Upon completion of the acquisition, the company's direct interest in Xinbeijiang Pharmaceutical will increase from approximately 90.64% to approximately 90.77%.

Zhonghuiyuan serves as an employee shareholding platform for Xinbeijiang Pharmaceutical. In order to further optimize Xinbeijiang Pharmaceutical's equity structure, strengthen the company's control over its core active pharmaceutical ingredient subsidiary, and improve operational decision-making efficiency, the company intends to acquire a portion of the Xinbeijiang Pharmaceutical shares held by Zhonghuiyuan.

This transaction is a normal business arrangement for the company to optimize subsidiary governance and deepen its industrial layout. It aligns with the company's overall strategic development plan and serves the company's long-term development interests as well as the overall interests of all shareholders.

The transaction will not result in any significant changes to the company's current or future financial condition and operating results, nor will it have any adverse impact on the company's daily operations.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10